S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

BMY Bristol Myers Squibb Co

55.91

0.00 (0.00%)

Pre Market

Last Updated: 03:40:41

Delayed by 15 minutes

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

Both Shuttle Pharmaceuticals (Nasdaq:SHPH) and Northwest Biotherapeutics

To read the full story on AllPennyStocks.com, click here.

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Bristol Myers Squibb Charts.

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Bristol Myers Squibb Charts.

Bristol Myers Squibb Co News

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments
Monday 13 January 2025 (3 days ago) • AllPennyStocks.com

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
Monday 13 January 2025 (3 days ago) • GlobeNewswire Inc.

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
Friday 3 January 2025 (2 weeks ago) • Business Wire

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
Friday 27 December 2024 (3 weeks ago) • Business Wire

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
Monday 23 December 2024 (3 weeks ago) • Business Wire

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Monday 23 December 2024 (3 weeks ago) • Business Wire

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
Thursday 19 December 2024 (4 weeks ago) • Business Wire

Bristol Myers Squibb Announces Dividend Increase
Wednesday 11 December 2024 (1 month ago) • Business Wire

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
Monday 9 December 2024 (1 month ago) • Business Wire

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference
Tuesday 26 November 2024 (2 months ago) • Business Wire

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Tuesday 19 November 2024 (2 months ago) • Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Friday 15 November 2024 (2 months ago) • Business Wire

More Bristol Myers Squibb Co News Articles

Good Vibrations Shoes (PK)

Moon Equity (PK)

Brookmount Explorations (PK)

Decentral Life (PK)

Kraig Biocraft Laborator... (QB)

Enanta Pharmaceuticals

Tonix Pharmaceuticals

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions